Altimmune (ALT) Shares Outstanding (Weighted Average) (2010 - 2026)

Altimmune (ALT) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $124.5 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $124.5 million, up 64.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $124.5 million (up 64.75% YoY), and the FY2025 annual result was $88.1 million, changed N/A from the prior year.
• Shares Outstanding (Weighted Average) improved to $124.5 million in Q1 2026 per ALT's latest filing, from $88.1 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $124.5 million in Q1 2026 and troughed at $1.0 million in Q2 2022.
• A 5-year average of $55.6 million and a median of $70.8 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Weighted Average) tumbled 97.51% in 2022, then surged 6886.48% in 2024.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $1.0 million in 2022, then soared by 5145.15% to $53.2 million in 2023, then surged by 33.35% to $71.0 million in 2024, then rose by 24.08% to $88.1 million in 2025, then jumped by 41.27% to $124.5 million in 2026.
• Business Quant data shows ALT's Shares Outstanding (Weighted Average) at $124.5 million in Q1 2026, $88.1 million in Q4 2025, and $89.4 million in Q3 2025.